SHANK3 and premenstrual tension: In consideration of such variability in the pathogenic molecular mechanisms observed in PMS, therapeutic strategies aiming to address the consequences of SHANK3 haploinsufficiency may be promising for some of the neurodevelopmental traits of individuals with PMS but may fail to solve several other problems, particularly in subjects with large 22q13.3 deletions.